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Abstract The advent of anti-TNF agents has dramatically
changed the treatment algorithms for IBD in the last
15 years, but primarily and more importantly secondary
loss of response is often observed. Fortunately, new treat-
ment options have been actively explored and some have
already entered our clinical practice. In the class of anti-
cytokine agents, the anti-IL12/IL23 monoclonal antibodies
(mAbs) have entered clinical practice with the anti-p40
mAb ustekinumab in Crohn’s disease (CD). Also, more
selective anti-IL23 agents (anti-p19) have shown efficacy
and are being further developed, in contrast to agents
inhibiting IL-17 downstream which have failed in clinical
trials despite their clear efficacy in psoriasis (Verstockt
et al. in Expert Opin Biol Ther 17(1):31–47, 2017; Ver-
stockt et al. in Expert Opin Drug Saf 16(7):809–821, 2017).
Following up on the efficacy of the anti-adhesion molecule
vedolizumab, etrolizumab (anti-beta-7 integrin) and PF-
00547659, an anti-MadCam mAb, are being developed
(Lobaton et al. in Aliment Pharmacol Ther 39(6):579–594,
2014). Oral anti-trafficking agents, such as ozanimod, tar-
geting the S1P receptor responsible for the efflux of T-cells
from the lymph nodes, have also shown efficacy in patients
with ulcerative colitis (UC) (Sandborn et al. in N Engl J
Med 374(18):1754–1762, 2016). Oral agents inhibiting cell
signaling have been explored successfully in IBD. Tofac-
itinib, a non-selective oral Janus kinase (JAK) inhibitor, is
effective in patients with UC and several other more or less
selective Jak1, 2 and 3 inhibitors are being developed for
the treatment of CD and UC (Sandborn et al. in N Engl J
Med 376(18):1723–1736, 2017; Vermeire et al. in Lancet
389(10066):266–275, 2017; De Vries et al. in J Crohns
Colitis 11(7):885–93, 2017). Finally, despite initial disap-
pointing results with systemic administration of mes-
enchymal stem cells, Alofisel, adipose tissue derived,
allogeneic mesenchymal stem cells, locally injected in
perianal fistula tracts, induce long-lasting beneficial effects
and the drug has been approved in Europe (Panes et al. in
Gastroenterology, 2017). In summary, the quest for new
treatment options in IBD is very active and justified by the
high medical need and unresolved problems patients are
facing.
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Anti-IL12/IL23 agents
The non-selective anti-IL12/23 mAB ustekinumab (Ste-
lara, Janssen) has been tested in four large phase II/III
clinical trials in patients with IBD, and has been proven to
be efficacious to induce and maintain clinical remission in
CD [9–11]. This treatment has been approved before to
treat psoriasis and psoriatic arthritis, and is now also
approved in Europe and the US to treat patients with
Crohn’s disease. The long-term safety in a large prospec-
tive cohort is reassuring, but it has to be said that patients
with IBD comprised only 3% of that cohort. Most were
patients with psoriasis or rheumatologic conditions [12].
The results of a phase III, randomized, double-blind, pla-
cebo-controlled multicenter study to evaluate the safety
and efficacy of ustekinumab induction and maintenance
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therapy in subjects with moderate-to-severe UC (UNIFI,
NCT02407236) are expected (Table 1).
The role of ustekinumab pharmacokinetics is unclear at
this moment, but cohort data suggest that endoscopic
healing is related to ustekinumab trough levels [13], which
was also observed in a post hoc sub-analysis of the phase
III program [14]. In contrast to infliximab, the immuno-
genic profile of ustekinumab is very limited (2.3% of all
1154 patients included in the UNITI trials developed auto-
antibodies against ustekinumab, measured via a drug-tol-
erant assay) [11]. This might explain why immunomodu-
lators do not seem to influence ustekinumab
pharmacokinetics [14].
Though the efficacy and safety of blocking p40 has been
established, it is not clear if direct modulation of the IL12
axis via p40 contributes to the efficacy or has potential
risks related to IL120s role in tumor immune surveillance
and in host defense against intracellular pathogens [2].
Hence, selectively blocking IL23p19 might offer important
differentiation in efficacy and safety (Fig. 1).
MEDI2070 (AMG-139, Amgen and MedImmune) is a
fully human IgG2 monoclonal antibody, which selectively
binds p19. The results of a phase IIa induction study
recently demonstrated clinical efficacy in 121 patients with
moderate-to-severe CD, who previously had failed anti-
TNF therapy [15]. After administration of 700 mg
MEDI2070 intravenously at week 0–4, clinical effect
([ 100 drop from baseline CDAI-score OR CDAI\ 150)
at week eight was achieved in 49.2% of patients, compared
to 26.7% of patients receiving placebo (p = 0.010).
Through week 12, no increased rate of adverse events (AE)
with active treatment was observed compared to placebo.
Similarly to MEDI2070, risankizumab (BI-655066, Boeh-
ringer Ingelheim and Abbvie) potently binds to p19 and
prevents its binding to the IL23R. The results of a phase II
trial in moderately-to-severely active CD were favorable
[16]. Selective blockade of IL23p19 with risankizumab
was superior to placebo in achieving clinical remission
(30.5% vs 15.4% respectively, p = 0.049) and clinical
response (39.0% vs 20.5% respectively, p = 0.027).
Ninety-four per cent of all included patients had been
exposed to anti-TNF before, with approximately one-third
(30%) experiencing primary non-response and another
third (28%) secondary loss of response, reflecting a very
refractory population. In addition, significantly more
patients achieved endoscopic remission with risankizumab
Fig. 1 Pro-inflammatory cytokine pathways in IBD
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compared to placebo (17.1% vs 2.6%, respectively;
p = 0.002) at week 12. So far, risankizumab shows a
favorable safety profile with fewer severe or serious AE
reported compared to placebo. Although ustekinumab and
risankizumab have not yet been compared head-to-head in
IBD, a phase II randomized-trial in patients with psoriasis
showed superiority of risankizumab compared to ustek-
inumab [17].
LY3074828 (Eli Lilly) is actually being studied in
patients with moderate-to-severe UC (NCT02589665).
Tildrakizumab (MK-3222, Sun Pharma and Merck) will
potentially be studied in active CD, after the first positive
results of a phase IIa trial in psoriasis [18]. Finally,
guselkumab (Janssen Biotech) showed efficacy in a recent
phase II trial in psoriasis [19, 20], and early trials in
patients with IBD are underway.
Targeting IL17, a key cytokine secreted by TH17 cells
and downstream mediator of IL23 signaling, is logical as
an increased expression of IL17A and IL17F has been
reported in active CD, scattered throughout the submucosa
and muscularis propria [21, 22]. Brodalumab (AMG827,
Amgen) is a fully human antibody against the IL17-re-
ceptor A (IL17RA), studied in a phase II trial in moderate-
to-severe CD. The study was terminated prematurely after
an independent review of unblinded safety data from 117
of 216 planned subjects demonstrated an imbalance in
worsening CD in active treatment groups [23]. Secuk-
inumab (AIN457, Novartis) is a fully humanized selective
anti-IL17A antibody (Fig. 1), studied in CD after increased
expression of IL17A mRNA was reported in the intestinal
mucosa of CD patients [24]. Phase I-II trials in psoriasis
and rheumatoid arthritis showed clinically relevant
responses and a head-to-head comparative trial in patients
with plaque psoriasis showed superiority for secukinumab
over the anti-p40 ustekinumab [25]. Nevertheless, an RCT
in moderate-to-severe CD demonstrated blockade of IL17A
was ineffective and secukinumab may even worsen disease
in patients with a certain genotype. In addition, higher rates
of AE, mainly serious infections (mucocutaneous can-
didiasis) were noted compared to placebo [26].
The fact that blockade of either the ligand (secuk-
inumab) or its receptor (brodalumab) causes worsening
disease, suggests this is not merely coincidence but prob-
ably a true biologic effect. The worsening comes not
entirely unexpected, as IL17A has been claimed to show
both a protective and exacerbating effect in preclinical
murine models [2]. Both RCTs clearly point out that
blocking IL17/IL17R may interfere with a protective
function of IL17 in the intestine.
Anti-adhesion molecules
Vedolizumab (Entyvio, Takeda), a mAb targeting a4b7
integrins resulting in a gut selective mechanism of action
(Fig. 2), has been approved for the treatment of moderate
to severe Crohn’s disease and ulcerative colitis worldwide.
Natalizumab, a non-selective anti-a4 integrin mAb, had
been shown to be effective in Crohn’s disease before, but is
only available to treat Crohn’s disease in the US and
Switzerland. Other jurisdictions have not approved this
drug since it carries a risk of a potentially deadly viral brain
disease, progressive multifocal leukencephalopathy [3].
The long-term risk in patients with multiple sclerosis
treated long term is estimated at 1/300. With vedolizumab,
no cases have been reported so far in over 72,000 exposed
patients.
Etrolizumab (Genentech-Roche) is a slightly less gut
selective mAb targeting the beta7 integrin subunit and thus
both alpha4beta7 and aEbeta7. This could potentially
increase its efficacy as aEb7 integrins, through their bind-
ing to E-cadherin, are responsible for retention of lym-
phocytes in the diseased tissue. On the other hand, this
broader mechanism of action may result in a loss of gut
selectivity and thus in more systemic side-effects. Etroli-
zumab was proven to be efficacious in a phase IIb trial in
moderate to severe ulcerative colitis [27]. The remission
rates in the 100 mg and 300 mg SC group combined were
significantly better than placebo (10% 300 mg, 21%
100 mg, 0% placebo, p = 0.048 and p = 0.004 respec-
tively). Of note, etrolizumab at either dose of 100 and
300 mg was not more effective than placebo in patients
who had already been treated with anti-TNF agents before.
A large phase III trial is currently recruiting patients.
Inhibiting mucosal addressin cellular adhesion molecule
1 (MadCAM-1), the ligand of a4b7 integrin, also is a gut-
selective anti-adhesion molecule strategy. The anti-Mad-
CAM-1 m Ab, PF-00547, 659 (Pfizer and Shire) has been
tested in both Crohn’s disease and ulcerative colitis, but
clear significant improvements over placebo of clinical
disease activity have not been shown yet [28].
Fingolimod, an oral anti-adhesion molecule targeting
the S1P receptor, is used in clinical practice in patients with
multiple sclerosis. The binding of S1P to its receptor,
guides lymphocytes out of the lymph nodes and therefore,
interfering with this mechanism, results in a sequestration
of lymphocytes in the lymph nodes. Ozanimod, an S1P
receptor antagonist, has shown efficacy in patients with
moderate-to-severe ulcerative colitis. Ozanimod 1 mg, but
not the lower dose of 0.5 mg, was significantly superior to
placebo (ozanimod 1 mg 16.4%, ozanimod 0.5 mg 13.8%;
placebo 6.2%; p = 0.048 and p = 0.14 respectively) [4].
Both doses were better than placebo at inducing mucosal
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healing. Other similar molecules are being developed to
treat IBD. S1P receptors carry a risk of systemic infections,
including JC virus induced brain infections, and brad-
yarrhythmia, but this risk may vary based on the S1P
receptor subtypes targeted by the different compounds.
Janus kinase inhibitors
The Janus kinase (JAK) enzymes, named after the two-
faced Roman god Janus, are crucial in the signaling of a
variety of cytokines through their receptor and always
occur in heterodimers. Different combinations of JAK 1, 2,
3 and Tyrosine kinase (TYK) 2 are involved in the sig-
naling of key inflammatory cytokines. The specificity of a
molecule for the different JAK subtypes therefore will
determine its efficacy and safety profile. The non-selective
JAK inhibitor tofacitinib (Pfizer) is approved in Europe and
other parts of the world for the treatment of rheumatoid
arthritis. Also, in moderate to severe ulcerative colitis,
tofacitinib at a dose of 3 to 15 mg BID is more effective
than placebo to induce clinical remission [5]. The results of
two large phase III trials (Octave 1 and 2) confirm the
efficacy at inducing remission in ulcerative colitis, and the
Table 1 Overview of molecules in clinical development for IBD
MOA CD UC
Cytokine/chemokine MED2070/Risankizumab/Guselkumab (anti-IL23p19) Ustekinumab
(’Selective’)
anti-adhesion
molecules
Etrolizumab
PF-00547,659 (anti MadCam)
AMG 181
Ozanimod
Alicaforsen
Barrier/microbiota Fecal transplantation
Signaling Filgotinib, upadacitinib Tofacitinib
Cell based Mesenchymal stem cells (Alofisel)
MOA mechanism of action, Cd Crohn’s disease, UC ulcerative colitis
Fig. 2 Anti-integrins
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results of the maintenance phase of these trials indicate that
tofacitinib is also effective at maintaining remission
throughout one year [5]. On the other hand, tofacitinib
failed to show clinical efficacy in Crohn’s disease [29].
Other compounds, such as the more JAK1 selective filgo-
tinib (Galapagos/Gilead) and upadacitinib (Abbvie) are
being developed to treat Crohn’s disease and ulcerative
colitis. Filgotinib is more effective than placebo to induce
clinical remission and mucosal healing in patients with
moderate to severe Crohn’s disease [6]. Results from a
phase II RCT with upadacitinb are also showing dose
dependent favorable outcomes in patients with Crohn’s
disease [30]. JAKinibs are associated with an increase in
herpes zoster infections and potentially with other systemic
infections, serum lipid disturbances and anemia [7].
Ongoing phase III trials may elucidate whether the safety
profile is determined by the selectivity of compounds for
JAK1,2,3 and Tyk2 respectively.
Fecal microbiota transplantation
Treating IBD with fecal material has been tried for more
than 2000 years. All data available until recently, were
uncontrolled [31]. However, the renewed interest in the
intestinal microbiome as a modifier of human disease, has
led to randomized controlled trials using fecal transplan-
tation in patients with ulcerative colitis. Most of the fecal
mass is comprised of microbiota, and therefore the term
fecal microbiota transplantation (FMT) has been used. In
total, 3 out of the 4 RCTs with FMT which have been
performed in recent years, show a significant and favour-
able effect in inducing clinical and/or endoscopic remission
in patients with UC [32–35]. Nevertheless, more research is
needed on the ideal microbiome composition and FMT
conditions, such as mode and intensity of administration, to
treat UC and CD.
Nucleotides
The oral anti-sense small oligonucleotide Mongersen
(Guliani/Cellgene) is directed against the translation of
SMAD7. This is a key inhibitory protein that downregu-
lates the signaling of Transforming growth factor-beta
(TGF-b). When SMAD7 protein is suppressed, TGF-b will
be able to resort its anti-inflammatory effects on the
mucosa. The first RCT with Mongersen indicated that this
molecule is efficacious to induce clinical remission in
patients with Crohn’s disease. Mongersen at the higher
doses of 40 and 160 mg given daily for 14 days was better
than placebo at inducing Crohn’s disease remission [36]. In
addition, Mongersen induced a long-lasting response off
therapy [37]. However, a confirmatory randomized control
trial was stopped prematurely because of lack of efficacy
and the further development of this drug has been halted.
Mesenchymal stem cells
Stem cell therapy has not been successful in IBD until the
advent of mesenchymal stem cell therapy to treat perianal
Crohn’s disease. Cx-601, Alofisel (Tigenix/Takeda) has
proven to be efficacious to induce and maintain fistula
closure, when applied locally close to the tract in con-
junction with surgical preparation of the fistula track [8].
Of note, a high placebo effect was noted in this trial, which
could have been due to the background therapies including
anti-TNFs and the surgical preparation of the fistula track
with closing of the internal orifice in both treatment arms.
The drug received approval in Europe and a second phase
III trial is being conducted.
Summary
The landscape of IBD treatment is widening rapidly. As
more biologic and small molecule therapies become
available, patients and clinicians alike will be faced with
selecting the right drug. The mechanisms of action and
perceived tolerability of new treatment options will
increasingly drive clinical decisions. Head-to-head com-
parative trials are desperately needed to facilitate these
important choices.
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